Learn About DRIPS
Start a DRIP

News and Views
DRIP of the Week
DRIPs A to Z

Free Trial!
Advertise With Us
Terms of Service
Contact Us
About Us


Monday, 02/24/2003

PFE - Pfizer

Company Description

Pfizer Inc. is a research-based, global pharmaceutical company. The Company discovers, develops, manufactures and markets prescription medicines for humans and animals as well as many consumer products. The Company operates in two business segments: Pharmaceuticals and Consumer Products. The Pharmaceuticals segment includes prescription pharmaceuticals for treating cardiovascular diseases, infectious diseases, central nervous system disorders, diabetes, urogenital conditions, allergies, arthritis and other disorders; products for food animals and companion animals; and the manufacture of empty gelatin capsules. The Consumer Products segment includes self-medications, shaving and fish food and fish care products, as well as confectionery products consisting of chewing gums, breath mints and cough tablets.

Reasons to Invest

By every measure, 2002 was another outstanding year for Pfizer. Revenue growth was led by the Company's human pharmaceutical operations, which achieved fourth-quarter revenues of $8.253 billion (up 15 percent) and full-year revenues of $28.288 billion (up 12 percent).

Thanks to the hard work and talent of the people of Pfizer, the company has achieved double-digit revenue growth, and even stronger earnings growth, while continuing to fund the world's largest private discovery and development efforts seeking new and better prescription medicines. Pfizer met the needs of millions of patients around the world as they market eight of the world's 30 largest-selling medicines, and four of the top 10. On a stand-alone basis, Pfizer is exceptionally well positioned to maintain a strong momentum in 2003 and beyond. The acquisition of Pharmacia will give them an even stronger global platform for discovering, developing, manufacturing, and marketing innovative medicines and consumer products."

The Pfizer Inc. Shareholder Investment Program is intended to promote long-term ownership in Pfizer. The Program offers:

Direct Purchase: If you do not yet own any shares of Pfizer stock, you may enroll in the program by completing an authorization form and returning it to the Administrator with a check or money order for $500 or more up to a maximum of $120,000 in U.S. dollars. There is no enrollment fee.

Purchase of Additional Shares and Automatic Monthly Bank Debits: You may buy additional shares of Pfizer stock as often as weekly in an amount of at least $50 in U.S. dollars. You may also purchase Pfizer stock by authorizing automatic monthly debits from your bank account. Amounts must be at least $50 a month. Your combined investment may not exceed $120,000 in any one calendar year. You pay no fees for these investments.

Dividend Reinvestment: You may elect to reinvest the cash dividends on all or a portion of your Pfizer shares. Pfizer pays dividends on both whole and fractional shares in the Program and will credit your account with the whole and fractional shares that are purchased with your dividends

Shares to Qualify = 1          
Auto-reinvestment = yes
Min/Max = $250 to $120,000 annually

Reinvestment Fees -

Dividend investment fees: None
Cash investment fees: None
Auto reinvestment fees: None

Pfizer's Transfer agent contact:

EquiServe Trust Company, N.A.
P.O. Box 43069
Providence, RI 02940-3069
(800) PFE-9393


Copyright 2003

Do not duplicate or redistribute in any form.
          Privacy Statement   Disclaimer   Terms Of Service